公开(公告)号：JP2013177405A

公开(公告)日：2013-09-09

申请号：JP2013091454

申请日：2013-04-24

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

IPC: C07K16/24 ,  A61K39/395 ,  A61P1/04 ,  A61P1/14 ,  A61P1/16 ,  A61P3/10 ,  A61P5/00 ,  A61P7/06 ,  A61P9/02 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/32 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P31/14 ,  A61P31/18 ,  A61P31/20 ,  A61P33/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C12N15/02 ,  C12N15/09 ,  C12P21/08

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

Abstract: PROBLEM TO BE SOLVED: To provide an antibody that binds with IL-12p40 binding protein, particularly human interleukin 12 (hIL-12) and/or human IL-23 (hIL-23), especially a chimera antibody, a CDR graft antibody and a humanized antibody.SOLUTION: A preferred antibody has a high affinity to hIL-12 and/or hIL-23, and neutralizes hIL-12 and/or hIL-23 activity in vitro and in vivo. The present antibody may be a full length antibody or an antigen binding part thereof. The present antibody or antibody part is useful for example to detect hIL-12 and/or hIL-23, and to inhibit hIL-12 and/or hIL-23 activity in human subject having a disorder harmfully caused by hIL-12 and/or hIL-23 activity.

Abstract translation: 要解决的问题：提供与IL-12p40结合蛋白特别是人白介素12（hIL-12）和/或人IL-23（hIL-23），特别是嵌合体抗体，CDR移植抗体和 人源化抗体。解决方案：优选的抗体对hIL-12和/或hIL-23具有高亲和力，并且在体外和体内中和hIL-12和/或hIL-23活性。 本抗体可以是全长抗体或其抗原结合部分。 本抗体或抗体部分例如可用于检测hIL-12和/或hIL-23，并且抑制hIL-12和/或hIL-23活性，其具有由hIL-12和/或 hIL-23活动。

公开(公告)号：WO2007005608A3

公开(公告)日：2008-10-09

申请号：PCT/US2006025584

申请日：2006-06-29

Applicant: ABBOTT LAB ,  LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

Inventor： LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

IPC: C07K16/00

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

Abstract translation: 本发明包括IL-12p40结合蛋白，特别是结合人白细胞介素-12（hIL-12）和/或人IL-23（hIL-23）的抗体。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-12和/或hIL-23具有高亲和力，并在体外和体内中和h IL-12和/或hIL-23活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-12和/或hIL-23和用于抑制hIL-12和/或hIL-23活性，例如在患有hIL -12和/或hIL-23活性是有害的。

公开(公告)号：WO2012024650A3

公开(公告)日：2012-05-31

申请号：PCT/US2011048518

申请日：2011-08-19

Applicant: ABBOTT LAB ,  LACY SUSAN E ,  BARBON JEFFREY A ,  CHHAYA MEHA ,  FUNG EMMA ,  HUTCHINS CHARLES W ,  LANG DIANE M ,  BARLOW EVE H ,  LEDDY MARY ,  CHARI RAVI

Inventor： LACY SUSAN E ,  BARBON JEFFREY A ,  CHHAYA MEHA ,  FUNG EMMA ,  HUTCHINS CHARLES W ,  LANG DIANE M ,  BARLOW EVE H ,  LEDDY MARY ,  CHARI RAVI

IPC: C07K16/22

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/50 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/566

Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and caninized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.

Abstract translation: 本公开内容涵盖NGF结合蛋白，特别是嵌合抗体，CDR移植和可插入抗体的抗体及其制备及其用途的方法。 本公开的抗体或抗体部分可用于检测NGF和抑制NGF活性，例如在患有NGF活性有害的病症的哺乳动物受试者中。

公开(公告)号：WO2005100403A3

公开(公告)日：2006-07-13

申请号：PCT/US2005011956

申请日：2005-04-08

Applicant: ABBOTT LAB ,  REILLY EDWARD B ,  LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  ROGUSKA MICHAEL

Inventor： REILLY EDWARD B ,  LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  ROGUSKA MICHAEL

IPC: C07K16/28 ,  A61K39/395 ,  C12N5/10 ,  C12N15/13 ,  C12N15/63 ,  C12Q1/70 ,  G01N33/53

CPC classification number: C07K16/2863 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2317/92

Abstract: The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies and antigen-binding portions, methods of treatment, as well as pharmaceutical compositions comprising said antibodies and antigen-binding portions.

Abstract translation: 本发明涉及结合并激活促红细胞生成素受体的抗体及其抗原结合部分。 本发明还涉及编码这种抗体和抗原结合部分的核酸序列。 本发明还涉及使用所述抗体和抗原结合部分，治疗方法以及包含所述抗体和抗原结合部分的药物组合物来激活哺乳动物中促红细胞生成素受体的内源性活性的方法。

公开(公告)号：EP1907421A4

公开(公告)日：2012-03-28

申请号：EP06785967

申请日：2006-06-29

Applicant: ABBOTT LAB

Inventor： LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

公开(公告)号：CR20130153A

公开(公告)日：2013-05-23

申请号：CR20130153

申请日：2013-04-03

Applicant: ABBOTT LAB

Inventor： LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

IPC: C07K16/00

Abstract: Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados.

公开(公告)号：CR20130150A

公开(公告)日：2013-05-23

申请号：CR20130150

申请日：2013-04-03

Applicant: ABBOTT LAB

Inventor： LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

IPC: C07K16/00

Abstract: Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados. Los anticuerpos preferidos tienen gran afinidad por hIL-12 y/o hIL-23 y neutralizan la actividad de hIL-12 y/o hIL-23 in vitro y in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa o una porción de unión al antígeno del mismo. También se provee un método de elaboración y un método de uso de los anticuerpos de la invención.

公开(公告)号：BRPI0611714A2

公开(公告)日：2009-01-13

申请号：BRPI0611714

申请日：2006-06-29

Applicant: ABBOTT LAB

Inventor： LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

IPC: C07K14/715

Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

公开(公告)号：MXPA06011673A

公开(公告)日：2007-01-23

申请号：MXPA06011673

申请日：2005-04-08

Applicant: ABBOTT LAB

Inventor： REILLY EDWARD B ,  ROGUSKA MICHAEL ,  LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P

IPC: A61K39/395 ,  C07K16/28 ,  C12N5/10 ,  C12N15/13 ,  C12N15/63 ,  C12Q1/70 ,  G01N33/53

Abstract: La presente invencion se refiere a anticuerpos y sus porciones de union de antigeno que se unen a y activan un receptor de eritropoyetina. La invencion tambien se refiere a secuencias de acido nucleico que codifican dichos anticuerpos y porciones de union de antigeno. La presente invencion ademas se refiere a metodos para activar la actividad endogena de un receptor de eritropoyetina en un mamifero utilizando dichos anticuerpos y porciones de union de antigeno, metodos de tratamiento, asi como composiciones farmaceuticas que comprenden dichos anticuerpos y porciones de union de antigeno.

公开(公告)号：CA2563295A1

公开(公告)日：2005-10-27

申请号：CA2563295

申请日：2005-04-08

Applicant: ABBOTT LAB

Inventor： ROGUSKA MICHAEL ,  BELK JONATHAN P ,  FUNG EMMA ,  LACY SUSAN E ,  REILLY EDWARD B

IPC: C07K16/28 ,  A61K39/395 ,  C12N5/10 ,  C12N15/13 ,  C12N15/63 ,  C12Q1/70 ,  G01N33/53

Abstract: The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen- binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies and antigen-binding portions, methods of treatment, as well as pharmaceutical compositions comprising said antibodies and antigen- binding portions.